<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581789</url>
  </required_header>
  <id_info>
    <org_study_id>H-2007-0063</org_study_id>
    <secondary_id>CO05507</secondary_id>
    <secondary_id>H-2007-0063</secondary_id>
    <secondary_id>A534260</secondary_id>
    <secondary_id>SMPH\MEDICINE\HEM-ONC</secondary_id>
    <secondary_id>NCI-2011-00549</secondary_id>
    <nct_id>NCT00581789</nct_id>
  </id_info>
  <brief_title>Erlotinib and Sunitinib in NSCLC</brief_title>
  <official_title>Phase I Study of Erlotinib and Sunitinib in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in&#xD;
           patients with non-small cell lung cancer (NSCLC).&#xD;
&#xD;
        -  To determine response to sunitinib plus erlotinib in patients with non-small cell lung&#xD;
           cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib, sunitinib</intervention_name>
    <description>erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Sutent</other_name>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven stage IIIB (with pleural effusion or&#xD;
             pericardial effusion) or IV (either primary or recurrent) NSCLC (except squamous cell&#xD;
             histology).&#xD;
&#xD;
          -  Measurable disease per RECIST&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function&#xD;
&#xD;
          -  ECOG performance status 0, 1 or 2.&#xD;
&#xD;
          -  One and only one prior treatment with a chemotherapy regimen, including a platinum&#xD;
             based regimen for advanced disease (Stage IIIB with malignant effusion or Stage IV).&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Female patients must be surgically sterile, postmenopausal or agree to use effective&#xD;
             contraception during the period of therapy. Male patients must be surgically sterile&#xD;
             or agree to use effective contraception during the period of therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Squamous cell histology.&#xD;
&#xD;
          -  History of untreated brain metastases&#xD;
&#xD;
          -  Prior treatment with &gt;1 systemic chemotherapy-based regimens for advanced disease&#xD;
             (Stage IIIB with malignant effusion or Stage IV).&#xD;
&#xD;
          -  Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitors, or&#xD;
             other angiogenic inhibitors (including but not limited to bevacizumab, sunitinib,&#xD;
             erlotinib, gefitinib, or thalidomide).&#xD;
&#xD;
          -  Prior chemotherapy, radiation therapy, surgery, or investigational agent within 4&#xD;
             weeks prior to study entry, except palliative radiation therapy to a non-target&#xD;
             lesions (must have been completed 2 weeks prior to study enrollment).&#xD;
&#xD;
          -  Eligibility of patients receiving any medications or substances known to induce or&#xD;
             inhibit CYP3A4 and /or with the potential to affect the activity or pharmacokinetics&#xD;
             of sunitinib or erlotinib will be determined following review of their case by the&#xD;
             Principal Investigator.&#xD;
&#xD;
          -  NCI CTCAE grade 3 hemorrhage within 4 weeks of starting therapy.&#xD;
&#xD;
          -  Ongoing treatment with warfarin&#xD;
&#xD;
          -  Prior treatment with high-dose chemotherapy requiring stem cell rescue.&#xD;
&#xD;
          -  Prior irradiation to &gt;25% of the bone marrow (whole pelvis = 25%).&#xD;
&#xD;
          -  Diagnosis within prior 3 years of second malignancy, except basal cell carcinoma,&#xD;
             squamous cell skin carcinoma or in situ carcinoma that has been completely treated&#xD;
             without evidence of recurrent disease for 12 months.&#xD;
&#xD;
          -  Current treatment on another therapeutic clinical trial or receipt of another&#xD;
             investigative agent within 4 weeks of study entry.&#xD;
&#xD;
          -  Any of the following within 12 months prior to starting study treatment: myocardial&#xD;
             infarction, unstable angina, coronary/peripheral artery bypass graft, congestive heart&#xD;
             failure, cerebrovascular accident including transient ischemic attack, or pulmonary&#xD;
             embolus.&#xD;
&#xD;
          -  Hypertension (&gt;150/100mmHg) that cannot be controlled with standard antihypertensive&#xD;
             agents.&#xD;
&#xD;
          -  Ongoing cardiac dysrhythmias of grade &gt;2, â‰¥ grade 3 atrial fibrillation, or QTc&#xD;
             interval of &gt;450 msec for males and &gt;470 msec for females.&#xD;
&#xD;
          -  Evidence of hemoptysis &lt;4 weeks of starting study treatment.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality&#xD;
&#xD;
          -  HIV-positive patients&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Traynor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>erlotinib</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

